Alembic Pharmaceuticals Ltd
NSE:APLLTD

Watchlist Manager
Alembic Pharmaceuticals Ltd Logo
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Watchlist
Price: 1 035.45 INR -0.93%
Market Cap: 203.5B INR
Have any thoughts about
Alembic Pharmaceuticals Ltd?
Write Note

Operating Margin
Alembic Pharmaceuticals Ltd

11.4%
Current
10%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.4%
=
Operating Profit
7.2B
/
Revenue
63.6B

Operating Margin Across Competitors

Country IN
Market Cap 203.5B INR
Operating Margin
11%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 755.8B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.1B USD
Operating Margin
28%
Country US
Market Cap 251.8B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Alembic Pharmaceuticals Ltd
Glance View

Market Cap
203.5B INR
Industry
Pharmaceuticals

Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.

APLLTD Intrinsic Value
963.73 INR
Overvaluation 7%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.4%
=
Operating Profit
7.2B
/
Revenue
63.6B
What is the Operating Margin of Alembic Pharmaceuticals Ltd?

Based on Alembic Pharmaceuticals Ltd's most recent financial statements, the company has Operating Margin of 11.4%.